Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma

被引:166
作者
Grann, VR
Troxel, AB
Zojwalla, NJ
Jacobson, JS
Hershman, D
Neugut, AI
机构
[1] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA
[2] Columbia Univ, Med Ctr, Div Med Oncol, Dept Med, New York, NY USA
[3] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
关键词
hormone receptors; breast carcinoma; survival; Surveillance; Epidemiology; and End Results;
D O I
10.1002/cncr.21030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The objective of this study was to assess hormone receptor status as an independent predictor of survival in a population-based cohort of women with breast carcinoma who were followed for up to 11 years. METHODS. Since 1990, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program has collected data on hormone receptor status among patients with breast carcinoma. In a cohort of 205,736 women with breast carcinoma age >= 20 years at diagnosis who were entered into the SEER data base between 1990 and 2000, the authors analyzed the association of hormone receptor status with year of diagnosis, patient age, disease stage, tumor histology, tumor grade, race/ethnicity, and metropolitan/statewide residence areas. Kaplan-Meier survival curves were compared according to hormone receptor status, and Cox proportional-hazards regression models were used to assess the association of hormone receptor status with breast carcinoma-specific and all-cause mortality controlling for age, disease stage, tumor grade, tumor histology, race/ethnicity, and SEER region. RESULTS. Women who had tumors that were positive for both estrogen and progesterone hormone receptors had significantly better survival than other women with breast carcinoma in the overall cohort, within each stage, and in the younger and older age groups, although the survival advantage was greater among women age <= 50 years than among older women. Hormone receptor status was associated with mortality even when patient age, disease stage, tumor grade, tumor histology, race/ethnicity, and metropolitan/statewide residence areas were taken into account. CONCLUSIONS. Hormone receptor status was identified as an independent predictor of outcome in women with breast carcinoma. Data from clinical trials with long follow-up may shed light on whether and how the benefit of hormonal and other treatment varies with hormone receptor status.
引用
收藏
页码:2241 / 2251
页数:11
相关论文
共 46 条
[31]  
MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756
[32]   MISCLASSIFICATION BIAS RELATED TO DEFINITION OF MENOPAUSAL STATUS IN CASE-CONTROL STUDIES OF BREAST-CANCER [J].
MORABIA, A ;
FLANDRE, P .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1992, 21 (02) :222-228
[33]  
NAGAI MA, 1993, ONCOLOGY, V50, P412
[34]  
*NAT CANC I, 2002, PROGR
[35]  
NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO
[36]  
2-L
[37]   Generalizability of the surveillance, epidemiology, and end results registry population: Factors relevant to epidemiologic and health care research [J].
Nattinger, AB ;
McAuliffe, TL ;
Schapira, MM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (08) :939-945
[38]   Steroid hormone receptors in breast cancer management [J].
Osborne, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (03) :227-238
[39]   ASYMPTOTICALLY EFFICIENT RANK INVARIANT TEST PROCEDURES [J].
PETO, R ;
PETO, J .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1972, 135 :185-&
[40]   PROGNOSTIC-SIGNIFICANCE OF PROGESTERONE-RECEPTOR LEVELS IN ESTROGEN RECEPTOR-POSITIVE PATIENTS WITH METASTATIC BREAST-CANCER TREATED WITH TAMOXIFEN - RESULTS OF A PROSPECTIVE SOUTHWEST-ONCOLOGY-GROUP STUDY [J].
RAVDIN, PM ;
GREEN, S ;
DORR, TM ;
MCGUIRE, WL ;
FABIAN, C ;
PUGH, RP ;
CARTER, RD ;
RIVKIN, SE ;
BORST, JR ;
BELT, RJ ;
METCH, B ;
OSBORNE, CK .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1284-1291